Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

• Status: Recruiting
• Trial end date: 2020-10-30
• Target enrollment: 0
• Participant gender: All

Summary

Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Turin, Italy
• Treatments: Canagliflozin; Dapagliflozin; Empagliflozin; Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

• diabetic patients;

• clinical indication to SGLT2i therapy.

Exclusion Criteria:

• signs and symptoms of poor glycemic control (polydipsia, polyuria and weight loss);

• HbA1c >10% or 86 mmol/mol;

• Body Mass Index (BMI) > 40 Kg/m2;

• personal history of primary and secondary aldosteronism;

• personal history of heart failure;

• personal history of acute kidney injury;

• personal history of chronic kidney disease;

• personal history of liver cirrhosis;

• personal history of protein-wasting syndrome;

• personal history of renin secreting tumor;

• personal history of diabetes insipidus;

• personal history of syndrome of inappropriate antidiuresis (SIAD);

• personal history of hypocortisolism and hypercortisolism;

• therapy with Angiotensin Converting Enzyme inhibitors;

• therapy with Angiotensin Receptor Blockers;

• therapy with renin inhibitors;

• therapy with beta-blockers;

• therapy with alfa2-receptors agonists;

• therapy with Calcium Channel Blockers;

• therapy with diuretics;

• therapy with mineralocorticoid receptor antagonists;

• therapy with non steroidal and steroidal anti-inflammatory drugs.